Last $1.46 USD
Change Today -0.12 / -7.59%
Volume 14.9K
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

vycor medical inc (VYCO) Snapshot

Open
$1.58
Previous Close
$1.58
Day High
$1.58
Day Low
$1.26
52 Week High
07/10/14 - $3.12
52 Week Low
01/26/15 - $1.26
Market Cap
15.9M
Average Volume 10 Days
7.8K
EPS TTM
$-0.38
Shares Outstanding
10.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VYCOR MEDICAL INC (VYCO)

Related News

No related news articles were found.

vycor medical inc (VYCO) Related Businessweek News

No Related Businessweek News Found

vycor medical inc (VYCO) Details

Vycor Medical Inc. designs, develops, and markets neurological medical devices and therapies for neurosurgery in the United States and internationally. The company also develops non-invasive, computer-based therapies for those suffering from vision loss resulting from neurological trauma. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System (VBAS), a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer, and economical brain surgeries and a quicker patient discharge. It has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe, Korea, and Japan; and is seeking or has partial regulatory approvals in India, Russia, Taiwan, and Vietnam. The NovaVision segment develops and provides science-driven neurostimulation therapy and other medical technologies that help enhance and partially restore sight in patients with neurological vision impairments. It offers proprietary Visual Restoration Therapy (VRT) platform, which is clinically supported to enhance lost vision resulting from stroke, traumatic brain injury, or other acquired brain injuries; and Neuro Eye Therapy (NeET) in the European Union for enhancing visual sensitivity deep within the field defect. This segment also provides NeuroEyeCoach, an Internet-delivered saccadic training program that re-trains the ability of a patient to move their eyes, and re-integrate left and right vision. The company primarily serves patients, hospitals, and medical professionals. Vycor Medical, Inc. sells its products directly to hospitals through independent representatives, as well as through various distributors. The company was founded in 2005 and is headquartered in Boca Raton, Florida.

17 Employees
Last Reported Date: 11/12/14
Founded in 2005

vycor medical inc (VYCO) Top Compensated Officers

President and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

vycor medical inc (VYCO) Key Developments

Vycor Medical, Inc Presents at LD Micro Conference, Dec-03-2014 09:30 AM

Vycor Medical, Inc Presents at LD Micro Conference, Dec-03-2014 09:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States.

Vycor Medical, Inc Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Vycor Medical Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $334,339 against $321,630 a year ago. Operating loss was $437,788 against $484,201 a year ago. Net loss was $1,282,857 against $656,551 a year ago. Basic and diluted loss per share was $0.12 against $0.08 a year ago. Non-GAAP operating loss was $319,848 against $283,645 a year ago. Non-GAAP net comprehensive loss was $344,722 against $332,219 a year ago. Non-GAAP basic and diluted loss per share was $0.03 against $0.05 a year ago. For the nine months, the company reported revenue of $991,001 against $788,258 a year ago. Operating loss was $2,134,011 against $1,693,433 a year ago. Net loss was $2,060,202 against $1,299,066 a year ago. Basic and diluted loss per share was $0.33 against $0.29 a year ago. Non-GAAP operating loss was $1,057,408 against $1,201,579 a year ago. Non-GAAP net comprehensive loss was $1,176,345 against $1,339,984 a year ago. Non-GAAP basic and diluted loss per share was $0.12 against $0.22 a year ago.

Vycor Medical, Inc. Continues to Execute on its Stated Strategic Goal of Expanding Internationally

Vycor Medical Inc. announced that it had made significant in-roads into a number of key international markets. Most recently it has entered into a distribution agreement with Eurotech, and secured its first order. In addition to Russia, Vycor has identified and started to work with neurosurgical distributors in the following markets: Brazil, France, South Africa, Sri Lanka and Taiwan. In each of these markets, Vycor has entered into either evaluation or distribution agreements and is now going through local regulatory approvals. Including these countries, Vycor now has international agreements in place for VBAS in Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Holland, Hong Kong, Italy, Japan, Korea, Russia, South Africa, Spain, Sri Lanka, Sweden, Taiwan and the UK.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VYCO:US $1.46 USD -0.12

VYCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $84.75 USD +1.28
Integra LifeSciences Holdings Corp $57.59 USD +0.50
Medtronic Inc $75.59 USD -1.36
NuVasive Inc $46.83 USD +0.07
View Industry Companies
 

Industry Analysis

VYCO

Industry Average

Valuation VYCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VYCOR MEDICAL INC, please visit www.vycormedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.